Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.
about
Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionComparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.Pathogenesis of human immunodeficiency virus infectionStudies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes.Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1.Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in MacaquesAnti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activityV1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.Designing a soluble near full-length HIV-1 gp41 trimer.Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designImmunoregulatory effects of morphine on human lymphocytes.What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infectionThe Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures.Simian immunodeficiency virus DNA vaccine trial in macaques.Retention of viral infectivity after extensive mutation of the highly conserved immunodominant domain of the feline immunodeficiency virus envelope.Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein.Antibody reactivity to the immunodominant epitopes of the caprine arthritis-encephalitis virus gp38 transmembrane protein associates with the development of arthritisComplement activation by human monoclonal antibodies to human immunodeficiency virus.Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.Mechanism of neutralization of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B.Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms.Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope.KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV.Structural and functional properties of the membranotropic HIV-1 glycoprotein gp41 loop region are modulated by its intrinsic hydrophobic core
P2860
Q21245045-C1C0A290-374C-4FB5-87D8-F67909F17C55Q24538755-A9D4DE0E-4CAC-4045-8062-2E145763B0DBQ24634681-72E9DEB8-7237-496B-80F8-22D9EE216CC6Q24681784-8E07CFFD-4514-4054-AA0F-D589B9B49D47Q30358769-479EAB41-E548-450E-AAE0-299980F45469Q33784679-88BA5617-A487-4B20-A7BD-ECF978C8508CQ33786297-FA2D8B30-4E40-40A8-8848-FBFF1FF595DDQ33815502-2735202C-E43C-4685-BC08-2B17099D5F6BQ33819493-C5F342A6-007A-420B-9293-DF577331BDF8Q33826951-7EE355CA-44D5-436F-B861-CC675B03FBD2Q33874253-ADD20A40-CDF7-4462-A0D7-01E50D063298Q34306804-B9D9F48A-6032-4DC9-8601-7429A8AF5315Q34359035-7FA32FF2-9815-4B2F-934B-C17FBEE3D186Q34489464-FD156312-B50E-438B-9592-6D61448397ACQ34637968-D3793E09-05DD-440E-B162-8815AD7B0E12Q35196671-D96A1997-1D18-45D9-961D-B07F9734AE37Q35229000-9309382E-C71E-4C2C-9849-D24E7FD9C5D0Q35641144-52E89B81-DF71-4C3D-9125-7548BC85FF30Q35837798-D94BF9DA-EEEC-4611-B7C4-6F7FAA1588F4Q35851966-00386515-D080-402F-8F35-C953644FE6F8Q35861970-06F4D69D-7D19-4C5D-AEAC-3F90838E9D44Q35886295-2A51B486-41E2-4227-98A6-49F4A9CE26ACQ36230737-438E7F79-3A31-4B83-9CC7-C221FEE03ABDQ36549107-825E6BE1-180A-4450-8297-55862E57376CQ36630413-F1724F66-75C9-405B-AC6F-91B8E4C94552Q36636968-23903273-0D22-48DC-9AC0-529E80F920AFQ36638803-2B376D4D-0D2E-4F53-BDA6-4A6E11F4D4B1Q36654750-77FB2893-DC50-4B39-97C3-C3588B68A80FQ36781270-8167F395-51C6-45DA-8AE1-327CE668CF8FQ36978277-7896C8C4-B394-49B4-8920-8BD2DF52B77AQ37002517-29C9E76F-1210-49DC-9155-94C837371D15Q37256661-8E6B2B34-D967-46F2-97FE-5B69B7A927E0Q37348636-A5975044-3523-44A4-8368-764372E4000BQ37644037-11EFF6EE-3905-4ADB-9072-19CEC0777F6EQ39603619-CEA472E7-3C24-4204-B236-D9B0B7DB9B72Q39641765-16B43F25-08AE-47CE-8792-4872E1CFEDC0Q40106699-1F25C2B9-E736-4F27-BD9A-C9E5AA7802DDQ40145762-E06CE863-D237-4A35-B2F3-DEC594F02F2DQ40760920-BA5887F8-330D-4C53-85C2-625E49003C2BQ41783475-F80B22D0-A208-485A-9864-E9F630F0A8C5
P2860
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Two immunodominant domains of ...... rus type 1 infection in vitro.
@en
type
label
Two immunodominant domains of ...... rus type 1 infection in vitro.
@en
prefLabel
Two immunodominant domains of ...... rus type 1 infection in vitro.
@en
P2093
P2860
P1433
P1476
Two immunodominant domains of ...... rus type 1 infection in vitro.
@en
P2093
S Zolla-Pazner
W E Robinson
W M Mitchell
P2860
P304
P407
P577
1991-08-01T00:00:00Z